Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun;58(6):2792-2802.
doi: 10.1007/s12035-021-02295-z. Epub 2021 Jan 27.

Pharmacogenetic and Association Studies on the Influence of HLA Alleles and Rivastigmine on the Iranian Patients with Late-Onset Alzheimer's Disease

Affiliations

Pharmacogenetic and Association Studies on the Influence of HLA Alleles and Rivastigmine on the Iranian Patients with Late-Onset Alzheimer's Disease

Fatemeh Rezaei Rad et al. Mol Neurobiol. 2021 Jun.

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder affecting cognitive function. A number of allelic genes from HLA complex have shown variable associations with AD in different populations. In this study, we investigated the association of DQB1*06:00/x, DRB1*04:00/x, DRB1*15:00/x, and B*07:00/x genotypes with AD and their relevance to the efficacy of rivastigmine treatment in the Iranian population. Our findings suggest that DQB1*06:00/x genotype offers strong protection against AD (P = 0.0074), while B*07:00/x genotype imposes a significant susceptibility for sporadic Alzheimer's disease (SAD) (P = 0.009). Interestingly, B*07:00/x genotype does not show any apparent associations with familial Alzheimer's disease (FAD). Our studies also suggest a pharmacogenetic relationship between drug treatment and presence of a particular genotype in the Iranian LOAD patient population. The Clinical Dementia Rating analysis showed that LOAD patients carrying DRB1*04:00/x genotype tend to display a downward trend in the disease severity and symptoms after 2-year follow-up with rivastigmine treatment. Moreover, in our total patient population, the carriers of DQB1*06:00/x and B*07:00/x alleles have better and worse responses to rivastigmine respectively. We also measured the clinical relevance of the testing for these genotypes employing prevalence-corrected positive predictive value (PcPPV) formula. The PcPPV of testing for DQB1*06:00/x in the Iranian LOAD patients was 1.17% which means that people carrying this genotype have half of the probability of the absolute risk for developing LOAD, whereas the PcPPV of testing for B*07:00/x was 4.45% for SAD, which can be interpreted as a doubling chance for developing LOAD among the Iranian population carrying this genotype. These results also suggest that DQβ1 peptide containing positively charged AAs histidine30 and arginine55 and HLA class I β chain containing negatively charges aspartic acid114 and glutamic acid45,152 in their binding groove plays important roles in protection against and susceptibility for LOAD respectively.

Keywords: Alzheimer; HLA genes; PCR; Pharmacogenetic; Rivastigmine.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Wimo A, Guerchet M, Ali GC, Wu YT, Prina AM, Winblad B et al (2017) The worldwide costs of dementia 2015 and comparisons with 2010. Alzheimers Dement 13(1):1–7 - PubMed - PMC
    1. Steele NZR, Carr JS, Bonham LW, Geier EG, Damotte V, Miller ZA, Desikan RS, Boehme KL, Mukherjee S, Crane PK, Kauwe JSK, Kramer JH, Miller BL, Coppola G, Hollenbach JA, Huang Y, Yokoyama JS (2017) Fine-mapping of the human leukocyte antigen locus as a risk factor for Alzheimer disease: a case– control study. PLoS Med 14(3):e1002272. https://doi.org/10.1371/journal.pmed.1002272 - DOI - PubMed - PMC
    1. Candore G, Balistreri CR, Colonna-Romano G, Lio D, Caruso C (2004) Major histocompatibility complex and sporadic Alzheimer’s disease: a critical reappraisal. Exp Gerontol 39(4):645–652 - PubMed
    1. Rocca WA, Hofman A, Brayne C, Breteler MM, Clarke M, Copeland JR et al (1991) Frequency and distribution of Alzheimer’s disease in Europe: a collaborative study of 1980–1990 prevalence findings. Ann Neurol 30(3):381–390 - PubMed
    1. Zhang YW, Thompson R, Zhang H, Xu H (2011) APP processing in Alzheimer’s disease. Mol Brain 4(1):3 - PubMed - PMC

LinkOut - more resources